Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Brainstorm Cell Therapeutics Inc. (BCLI) had Debt to Equity Ratio of -0.11 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-3.85M |
|
-- |
|
-- |
|
$3.61M |
|
$-3.61M |
|
$-0.24M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.61M |
|
$-3.57M |
|
11.04M |
|
11.04M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$0.32M |
|
$0.15M |
|
$0.47M |
|
$0.79M |
|
$12.38M |
|
-- |
|
-- |
|
$12.38M |
|
$-11.60M |
|
$-11.60M |
|
$-11.60M |
|
11.04M |
|
| Cash Flow Statement Financials | |
$-2.21M |
|
$0.00M |
|
$2.15M |
|
$0.28M |
|
$0.21M |
|
$-0.07M |
|
$2.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.03 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-0.11 |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
33.24% |
|
33.24% |
|
-489.21% |
|
33.24% |
|
$-1.05 |
|
$-0.20 |
|
$-0.20 |
|